Literature DB >> 6257883

The cardiovascular and autonomic effects of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys.

A B Fredericks, N L Benowitz, C Y Savanapridi.   

Abstract

The cardiovascular effects of repeated dosing with delta-9-tetrahydrocannabinol (THC) were examined in chronically catheterized, conscious rhesus monkeys. THC (0.5 mg/kg) was administered i.v. every 6 hr for 3 weeks. Following the first THC bolus, a tachycardia (peak change, 34 beats/min) and hypotension (peak change, -21 mm Hg systolic blood pressure) sometimes preceded by a transient blood pressure increase were observed. Tolerance developed to the tachycardia and systolic blood pressure increase but not to the blood pressure decrease. Hourly measurement of systolic blood pressure and heart rate during the intervals between injections revealed heart rate decreases to which tolerance developed and blood pressure decreases which were sustained throughout the course of TCH dosing. Urinary catecholamine excretion increased during the 1st week of dosing and subsequently returned toward base-line levels. Control of basal heart rate and reflex heart rate changes was examined using autonomic agonists and antagonists. Heart rate decreases after beta adrenergic blockage (sotalol HCl) were attenuated, whereas heart rate increases after cholinergic blockade (atropine methylnitrate increases after cholinergic blockade (atropine methylnitrate) were augmented. Baroreceptor gain, measured as the ratio of heart rate change to systolic blood pressure change in response to phenylephrine, increased. The response of basal heart rate to antagonists and the augmented reflex bradycardia suggest that THC alters autonomic control of the cardiovascular system resulting in parasympathetic dominance. Divergent patterns of development of tolerance to heart rate and blood pressure effects suggest that THC affects heart rate and blood pressure through different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6257883

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?

Authors:  Barbara Malinowska; Marta Baranowska-Kuczko; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2.

Authors:  William R Arnold; Austin T Weigle; Aditi Das
Journal:  J Inorg Biochem       Date:  2018-04-07       Impact factor: 4.155

3.  Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.

Authors:  Jennifer L Stewart; Lance R McMahon
Journal:  J Pharmacol Exp Ther       Date:  2010-04-07       Impact factor: 4.030

4.  The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression.

Authors:  Nathalie Niederhoffer; Karin Schmid; Bela Szabo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-23       Impact factor: 3.000

5.  Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation.

Authors:  N Niederhoffer; B Szabo
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

6.  Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.

Authors:  V E Mendizábal; E Adler-Graschinsky
Journal:  Br J Pharmacol       Date:  2007-04-23       Impact factor: 8.739

Review 7.  Cannabinoid receptors in acute and chronic complications of atherosclerosis.

Authors:  F Mach; F Montecucco; S Steffens
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

8.  Tolerance and dependence to Δ9-tetrahydrocannabinol in rhesus monkeys: Activity assessments.

Authors:  Jenny L Wilkerson; David R Schulze; Lance R McMahon
Journal:  PLoS One       Date:  2019-03-12       Impact factor: 3.240

Review 9.  Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?

Authors:  Jolanta Weresa; Anna Pędzińska-Betiuk; Krzysztof Mińczuk; Barbara Malinowska; Eberhard Schlicker
Journal:  Cells       Date:  2022-03-28       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.